Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: IMO-B project; OXI 104

Latest Information Update: 26 May 2003

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OXiGENE
  • Developer Active Biotech; Genzyme Oncology; Harvard Medical School; OXiGENE; University of Texas System
  • Class Benzamides; Chemosensitisers; Small molecules
  • Mechanism of Action DNA repair enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Colorectal cancer; Inflammatory bowel diseases; Solid tumours

Most Recent Events

  • 15 May 2003 Discontinued - Preclinical for Inflammatory bowel disease in Sweden (PO)
  • 07 May 2002 Declopramide has been licensed to Active Biotech AB for World-wide rights
  • 30 Apr 2002 Preclinical trials in Inflammatory bowel disease in Sweden (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top